Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Apogee Therapeutics. The associated price target remains the same with $115.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Julian Harrison has given his Buy rating due to a combination of factors that highlight Apogee Therapeutics’ promising future prospects. The company’s APG777 Phase 2 APEX trial in atopic dermatitis has shown positive results, with the 16-week induction data demonstrating strong efficacy and a favorable safety profile. The upcoming 52-week maintenance data is expected to confirm its best-in-class status, which could further solidify its market position.
Additionally, Apogee’s financial health is robust, with sufficient cash reserves to fund operations well into 2028. The ongoing head-to-head trial of APG279 against Dupixent could provide further validation of Apogee’s innovative approach, potentially leading to higher efficacy rates. These strategic developments, combined with the potential for APG777 to differentiate itself in asthma treatment, underpin Harrison’s optimistic outlook and Buy recommendation.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.
APGE’s price has also changed slightly for the past six months – from $34.490 to $34.650, which is a 0.46% increase.